Quality & complianceOfficial

Safecor Health recalls metoclopramide tablets over co-mingled tablet; FDA classifies it Class II

🇺🇸 FDA enforcement report · Wed 04 Nov 2026

The FDA enforcement report lists an ongoing, nationwide Class II recall of metoclopramide tablets from Safecor Health, LLC, after a co-mingled tablet was identified.

Safecor Health, LLC is recalling batches of metoclopramide tablets in the United States after a co-mingled tablet was found, according to an entry in the FDA's enforcement report dated 4 November 2026.

The agency has classified the action as Class II and assigned it recall number D-0075-2027. Its status is listed as ongoing, and the product was distributed nationwide across the US.

The page text available for this item consists largely of search-tool and navigation content. It does not give the batch numbers, strengths, quantities, dates of distribution or any detail on how the co-mingling occurred, so those points cannot be confirmed here.

As general context, the FDA uses Class II for recalls where use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious harm is remote.

What it means for your team

  • Pharmacies, repackagers and institutional purchasers that handled Safecor Health metoclopramide tablets should check their stock against recall D-0075-2027 in the FDA enforcement report for lot details.
  • Quality teams may wish to review controls against mix-ups and co-mingling in repackaging and unit-dose operations.
  • Because the recall is ongoing, its scope and status could change, so teams should monitor the FDA database for updates.

Official source: FDA enforcement report ↗

Article written by VigiEye from the official source (FDA enforcement report). AI-assisted; check the source before acting.

More Quality & compliance All →